Urology 5th year, 1st lecture (Dr. Sarwar)

64
Benign prostatic Benign prostatic hyperplasia hyperplasia Prepared by Prepared by Dr.sarwar N mahmood Dr.sarwar N mahmood F.I.C.M.S( urology),F.E.B F.I.C.M.S( urology),F.E.B .U, E.A.U .U, E.A.U

description

The lecture has been given on Dec. 15th, 2010 by Dr. Sarwar.

Transcript of Urology 5th year, 1st lecture (Dr. Sarwar)

Page 1: Urology 5th year, 1st lecture (Dr. Sarwar)

Benign prostatic Benign prostatic hyperplasiahyperplasia

Prepared byPrepared by

Dr.sarwar N mahmoodDr.sarwar N mahmood

F.I.C.M.S( urology),F.E.B.U, E.A.UF.I.C.M.S( urology),F.E.B.U, E.A.U

Page 2: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 3: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 4: Urology 5th year, 1st lecture (Dr. Sarwar)

Incidence and epidemiologyIncidence and epidemiology

• Histologic BPH 20% in men aged 41-50 , to 50% in men 51-60% and to over 90% in men older than 80.

although clinical evidence of disease occurs less commonly.

• 55 year, approximately 25% of men report obstructive voiding symptoms (clinical BPH). at age of 75y, 50% of men complain of clinical BPH.

Page 5: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 6: Urology 5th year, 1st lecture (Dr. Sarwar)

Risk factorsRisk factors

• Genetic predisposition and some noted racial differences.

• 50% of men <60 year who undergo surgery for BPH may have heritable form.

• first degree male relatives of such patients carry an increase risk of 4 fold.

Etiology:• Multifactorial

Page 7: Urology 5th year, 1st lecture (Dr. Sarwar)

PathologyPathology

Fibro musculo glandular hyperplasia

Page 8: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 9: Urology 5th year, 1st lecture (Dr. Sarwar)

Clinical features Clinical features

Divide into obstructive and irritative symptoms

Page 10: Urology 5th year, 1st lecture (Dr. Sarwar)

Clinical featuresClinical features

Irritative voiding symptoms– Frequency

– Nocturia

– Urgency +/- incontinence

A strong, sudden desire to urinate is caused by hyperactivity and irritability of the bladder, resulting from obstruction,

In most circumstances, the patient is able to control temporarily the sudden need to void, but loss of small amounts of urine may occur (urgency incontinence).

Page 11: Urology 5th year, 1st lecture (Dr. Sarwar)

Obstructive voiding symptoms

Hesitancy Hesitancy in initiating the urinary stream is one of the early symptoms of bladder outlet obstruction. As the degree of obstruction increases, hesitancy is prolonged and the patient often strains to force urine through the obstruction. Prostate obstruction and urethral stricture are common causes of this symptom.

Loss of Force and Decrease of Caliber of the Stream Progressive loss of force and caliber of the urinary stream is noted as urethral resistance increases despite the generation of increased intravesical pressure. Terminal Dribbling

Terminal dribbling becomes more and more noticeable as obstruction progresses and is a most distressing symptom.

Clinical featuresClinical features

Page 12: Urology 5th year, 1st lecture (Dr. Sarwar)

Interruption of the Urinary Stream

Sense of Residual Urine The patient often feels that urine is still in the bladder even after urination has been completed

Acute Urinary Retention Sudden inability to urinate may supervene. The patient experiences increasingly agonizing suprapubic pain associated with severe urgency and may dribble only small amounts of urine.

Chronic Urinary Retention Chronic urinary retention may cause little discomfort to the patient . Constant dribbling of urine (paradoxic incontinence) may be experienced; it may be likened to water pouring over a dam.

.

Page 13: Urology 5th year, 1st lecture (Dr. Sarwar)

Clinical findingsClinical findingsphysical examination

DRE

focused neurological examination are performed on all patients.

The nervous system is examined to detect a neurological lesions

– Distended bladder.

– DRE of BPH usually result in smooth, firm, elastic enlargement of the

prostate .

– Prostate size estimated by DRE does not correlate with severity of

symptoms or degree of obstruction. DRE can roughly estimate the

true size of prostate and can’t assess the middle lobe.

Page 14: Urology 5th year, 1st lecture (Dr. Sarwar)

investigationinvestigation

• GUE (to exclude infection or hematuria).

• Renal function test (to asses renal function).

• PSA Measurement to detect prostate cancer

Page 15: Urology 5th year, 1st lecture (Dr. Sarwar)

2. imaging:

Upper tract imaging( IVP or renal ultrasound) indicated in the presence of concomitant UTI ,or complication of BPH (e.g., hematuria UTI, renal insufficiency , hx of stone disease).

3. Measurement of flow rate, determination of post-void residual urine, and pressure-flow studies are considered optional. urinary flow rates; in normal circumstances with a full bladder a maximal flow of 20 mL/s should be achieved

.

Page 16: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 17: Urology 5th year, 1st lecture (Dr. Sarwar)

4.Additional Tests Cystometrograms and Urodynamic profiles are reserved for patients with suspected neurological disease or those who have failed prostate surgery.

5.cystoscopy:

Should always be done immediately prior to prostatectomy, whether it is being done transurethrally or by open route to exclude a urethral stricture, bladder carcinoma, occasionally non opaque bladder stone

Page 18: Urology 5th year, 1st lecture (Dr. Sarwar)

Complications of bladder outlet Complications of bladder outlet obstructions:obstructions:

1.acute retention of urine

2. chronic retention with overflow incontinence

3.urinary tract infection.

4. vesical stone.

5.Hematuria.

6.Renal failure.

Page 19: Urology 5th year, 1st lecture (Dr. Sarwar)

TreatmentTreatmentTreatment options range from watchful waiting to surgery.

Absolute indications for surgery includes:

1. Refractory urine retention (failure to void after catheter removal).

2. Recurrent UTI from BPH.

3. Recurrent gross hematuria from BPH.

4. Bladder stone.

5. Chronic retention and renal insufficiency.

6. Large bladder diverticulum.

• Relative indications include failure of medical RX.

Page 20: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 21: Urology 5th year, 1st lecture (Dr. Sarwar)

Watchful waitingWatchful waiting

• For those with mild symptoms(symptom score 0-7), watchful waiting

is the appropriate management.

• Patient need to be seen 2-3 times per year to asses him for

progression.

Page 22: Urology 5th year, 1st lecture (Dr. Sarwar)

Medical treatmentMedical treatment

Page 23: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 24: Urology 5th year, 1st lecture (Dr. Sarwar)

Alpha blockersAlpha blockers

Classification Oral dosage

Non selective(phenoxybenzamine) 10 mg twice daily

Alpha-1 short actingPrazosin

Alfuzosin2mg twice daily

2-10mg daily(divided dose)

Alpha-1 long actingTerazosinDoxazosin

5 or10mg daily4 or 8 gm daily

Alpha-1a selectiveTamsulosin

.4 or .8 mg daily.

Page 25: Urology 5th year, 1st lecture (Dr. Sarwar)

Side effects include:

• Postural hypotension, dizziness, tiredness, rhinitis, retrograde

ejaculation, and headache

2) 5α-reductase inhibitors

Finasteride is a 5a-reductase inhibitor that blocks the conversion of

testosterone to dihydrotestosterone.

This drug affects the epithelial component of the prostate, resulting

in a reduction in the size of the gland and improvement in symptoms.

Six months of therapy are required to see the maximum effects on

prostate size (20% reduction) and symptomatic improvement.

.

Page 26: Urology 5th year, 1st lecture (Dr. Sarwar)

Side effects includes:

– decreased libido

– decrease ejaculatory volume,

– impotence.

Serum PSA is decreased by 50% in patients being treated with

finasteride

3) combination therapy

some time combination is useful in treating patient with BPH.

4) phytotherapy

Medical treatmentMedical treatment

Page 27: Urology 5th year, 1st lecture (Dr. Sarwar)

conventional surgical therapyconventional surgical therapy

Page 28: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 29: Urology 5th year, 1st lecture (Dr. Sarwar)

1.transurethral resection of prostate(TURP)1.transurethral resection of prostate(TURP)

Page 30: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 31: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 32: Urology 5th year, 1st lecture (Dr. Sarwar)

Risks of TURP include – retrograde ejaculation (75%), – impotence (5-10%),– incontinence (<1%).– Complications includes bleeding,– urethral stricture, or– bladder neck contracture,,– perforation of prostate capsule and extravasations ,– TUR syndrome

Page 33: Urology 5th year, 1st lecture (Dr. Sarwar)

TUR syndrome

resulting from a hypervolemic, hyponatremic state due to absorption

of the hypotonic irrigating solution.

Clinical manifestations of the TUR syndrome:

nausea, vomiting, confusion, hypertension, bradycardia, and visual

disturbances.

The risk of the TUR syndrome increases with resection times over

90 min. Treatment includes diuresis and, in severe cases,

hypertonic saline administration

Page 34: Urology 5th year, 1st lecture (Dr. Sarwar)

2. Transurethral incision of prostate 2. Transurethral incision of prostate (TUIP):(TUIP):

Page 35: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 36: Urology 5th year, 1st lecture (Dr. Sarwar)

3.open simple prostatectomy3.open simple prostatectomy

• Indicated when prostate is

– too big (>80-100gm) to be removed endoscopically

– concomitant bladder diverticulum

– vesical stone, is present

– if dorsal lithotomy positioning is not possible.

1. simple suprapubic prostatectomy (transvesically).

2. simple retropubic prostatectomy,

Page 37: Urology 5th year, 1st lecture (Dr. Sarwar)

Transvesical prostatectomyTransvesical prostatectomy

Page 38: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 39: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 40: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 41: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 42: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 43: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 44: Urology 5th year, 1st lecture (Dr. Sarwar)

Transvesical prostatectomyTransvesical prostatectomy

Page 45: Urology 5th year, 1st lecture (Dr. Sarwar)

retropubic prostatectomyretropubic prostatectomy

Page 46: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 47: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 48: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 49: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 50: Urology 5th year, 1st lecture (Dr. Sarwar)

minimally invasive therapyminimally invasive therapy

1.laser therapy:

2. transurethral vaporization of prostate (TUVP):

3. Transurethral hyperthermia (TUMT):

4. Transurethral needle ablation of the prostate (TUNA):

5. High intensity focused ultrasound (HIFU):

6. Intraurethral stents:

7. Transurethral dilation of prostate:

8. Permenant catheter:

– In unfit men with retention or associated dementia

Page 51: Urology 5th year, 1st lecture (Dr. Sarwar)

1.Laser therapy1.Laser therapy

Advantages of laser surgery include

(1) minimal blood loss.

(2) rare instances of TUR syndrome.

(3) ability to treat patients receiving anticoagulation therapy.

(4) ability to be done as an outpatient procedure.

Page 52: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 53: Urology 5th year, 1st lecture (Dr. Sarwar)

minimally invasive therapyminimally invasive therapy

1.laser therapy:

2. transurethral vaporization of prostate (TUVP):

3. Transurethral hyperthermia (TUMT):

4. Transurethral needle ablation of the prostate (TUNA):

5. High intensity focused ultrasound (HIFU):

6. Intraurethral stents:

7. Transurethral dilation of prostate:

8. Permenant catheter:

– In unfit men with retention or associated dementia

Page 54: Urology 5th year, 1st lecture (Dr. Sarwar)

2. transurethral vaporization of prostate 2. transurethral vaporization of prostate (TUVP):(TUVP):

Page 55: Urology 5th year, 1st lecture (Dr. Sarwar)

minimally invasive therapyminimally invasive therapy

1.laser therapy:

2. transurethral vaporization of prostate (TUVP):

3. Transurethral hyperthermia (TUMT):

4. Transurethral needle ablation of the prostate (TUNA):

5. High intensity focused ultrasound (HIFU):

6. Intraurethral stents:

7. Transurethral dilation of prostate:

8. Permenant catheter:

– In unfit men with retention or associated dementia

Page 56: Urology 5th year, 1st lecture (Dr. Sarwar)

3. Transurethral hyperthermia (TUMT):3. Transurethral hyperthermia (TUMT):

Page 57: Urology 5th year, 1st lecture (Dr. Sarwar)

minimally invasive therapyminimally invasive therapy

1.laser therapy:

2. transurethral vaporization of prostate (TUVP):

3. Transurethral hyperthermia (TUMT):

4. Transurethral needle ablation of the prostate (TUNA):

5. High intensity focused ultrasound (HIFU):

6. Intraurethral stents:

7. Transurethral dilation of prostate:

8. Permenant catheter:

– In unfit men with retention or associated dementia

Page 58: Urology 5th year, 1st lecture (Dr. Sarwar)

4. Transurethral needle ablation of the 4. Transurethral needle ablation of the prostate (TUNA):prostate (TUNA):

Page 59: Urology 5th year, 1st lecture (Dr. Sarwar)

TUNATUNA

Page 60: Urology 5th year, 1st lecture (Dr. Sarwar)

minimally invasive therapyminimally invasive therapy

1.laser therapy:

2. transurethral vaporization of prostate (TUVP):

3. Transurethral hyperthermia (TUMT):

4. Transurethral needle ablation of the prostate (TUNA):

5. High intensity focused ultrasound (HIFU):

6. Intraurethral stents:

7. Transurethral dilation of prostate:

8. Permenant catheter:

– In unfit men with retention or associated dementia

Page 61: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 62: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 63: Urology 5th year, 1st lecture (Dr. Sarwar)
Page 64: Urology 5th year, 1st lecture (Dr. Sarwar)